These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2023 related articles for article (PubMed ID: 7680764)

  • 21. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy for non-Hodgkin's lymphoma].
    Kuraishi Y; Usui N; Dobashi N
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
    Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
    Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Wang A; Luo Y; Wang Z
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):215-7. PubMed ID: 10920901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.
    Federico M; Moretti G; Gobbi PG; Avanzini P; Cavanna L; Carotenuto M; Lombardo M; Leone G; Pitini V; Abbadessa V
    Leukemia; 1991; 5 Suppl 1():95-101. PubMed ID: 1716340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
    Fisher RI
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.
    Fisher RI
    Cancer; 1994 Nov; 74(9 Suppl):2657-61. PubMed ID: 7525045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
    Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
    Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.